Published in Blood on December 01, 1990
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica (2011) 1.21
Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int J Nanomedicine (2010) 1.19
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica (2013) 1.11
In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med (2008) 1.07
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia (2010) 1.03
Biocompatibility of Fe₃O₄@Au composite magnetic nanoparticles in vitro and in vivo. Int J Nanomedicine (2011) 1.00
Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer (1994) 0.99
In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer (1991) 0.93
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res (2014) 0.91
Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. Leukemia (2013) 0.88
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer (2006) 0.86
Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov (2016) 0.83
MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle (2014) 0.83
Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia. Br J Cancer (1992) 0.82
Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol (2012) 0.81
Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia. World J Urol (2004) 0.80
In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer (1995) 0.78
Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. J Hematol Oncol (2015) 0.78
Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia. Haematologica (2009) 0.78
Oncogramme, a new individualized tumor response testing method: application to colon cancer. Cytotechnology (2010) 0.77
Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia (2015) 0.77
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia (2016) 0.75
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer. Yonsei Med J (2014) 0.75
Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts. BMC Cancer (2005) 0.75
On the interdigitating cells in the thymus-dependent area of the rat spleen: a relation between the mononuclear phagocyte system and T-lymphocytes. Cell Tissue Res (1974) 2.20
In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood (1995) 2.00
Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet (1997) 1.89
Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia. Leukemia (2001) 1.84
Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood (1998) 1.69
Investigation and standardization of the conditions for micro-lymphocyte cultures. Tissue Antigens (1973) 1.62
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia (2010) 1.57
White pulp compartments in the spleen of rats and mice. A light and electron microscopic study of lymphoid and non-lymphoid celltypes in T- and B-areas. Cell Tissue Res (1975) 1.54
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia (2006) 1.53
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia (2005) 1.50
The prognosis of oncologic patients in the pediatric intensive care unit. Intensive Care Med (1996) 1.45
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia (1999) 1.44
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia (2002) 1.42
Primary spinal epidural extraosseous Ewing's sarcoma. Cancer (1991) 1.39
Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun (2000) 1.30
Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders. J Thorac Cardiovasc Surg (1993) 1.29
In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood (1997) 1.28
Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet (1991) 1.26
Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci U S A (1994) 1.25
Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res (1995) 1.24
Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett (1988) 1.21
Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood (1999) 1.20
Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia (2005) 1.19
Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants. Leukemia (1998) 1.16
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am J Trop Med Hyg (2001) 1.16
High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol (1996) 1.16
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia (2002) 1.16
Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol (1996) 1.15
Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), HLA-DR, and a T cell marker may represent prothymocytes. J Immunol (1985) 1.11
Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia (1997) 1.10
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood (2000) 1.10
Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients--updated published cases and 16 new observations. Leukemia (1993) 1.08
Clinical scores for acute asthma in pre-school children. A review of the literature. J Clin Epidemiol (1994) 1.08
mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia (2000) 1.05
Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol (2000) 1.03
Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer (2001) 1.03
Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia (1991) 1.03
Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma (1994) 1.01
Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer (1994) 0.99
Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer (2003) 0.98
Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Med Pediatr Oncol (2000) 0.98
Lymphocyte capping and lymphocyte migration as associated events in the in vivo antigen trapping process. An electron-microscopic autoradiographic study in the spleen of mice. Cell Tissue Res (1975) 0.97
Human T cell leukemias with continuous V(D)J recombinase activity for TCR-delta gene deletion. J Immunol (1997) 0.97
t(7;12)(q36;p13) and t(7;12)(q32;p13)--translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia (2001) 0.97
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia (2004) 0.97
Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol (1997) 0.95
Histochemistry and electron microscopy of follicle lining reticular cells in the rat spleen. Z Zellforsch Mikrosk Anat (1971) 0.95
Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. J Infect Dis (1996) 0.94
Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome. Leukemia (2006) 0.94
In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer (1991) 0.93
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood (2000) 0.92
Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia (1997) 0.92
Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother Pharmacol (1986) 0.92
TEL/AML1 fusion is not a prognostic factor in Dutch childhood acute lymphoblastic leukaemia. Br J Haematol (2001) 0.92
Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer (1989) 0.91
Extensive junctional diversity of gamma delta T-cell receptors expressed by T-cell acute lymphoblastic leukemias: implications for the detection of minimal residual disease. Leukemia (1991) 0.91
Translocation (6;9) may be associated with a specific TdT-positive immunological phenotype in ANLL. Leukemia (1988) 0.91
Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk Res (1992) 0.91
Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia (1995) 0.90
The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer (1997) 0.90
The immotile cilia syndrome: phase contrast light microscopy, scanning and transmission electron microscopy. Pediatrics (1980) 0.89
Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. Leukemia (1999) 0.89
DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects. Biochem Pharmacol (1988) 0.88
Late psychosocial consequences for parents of children who survived cancer. J Pediatr Psychol (1995) 0.88
Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia (1995) 0.88
T- and B-areas in immune reactions. Volume changes in T and B cell compartments of the rat spleen following intravenous administration of a thymus-dependent (SRBC) and a thymus-independent (paratyphoid vaccin-endotoxin) antigen. A histometric study. Z Immunitatsforsch Exp Klin Immunol (1976) 0.88
Long-term effects of treatment for acute lymphoblastic leukemia with and without cranial irradiation on growth and puberty: a comparative study. Pediatr Res (1993) 0.88
Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer (1997) 0.87